ABIONYX Pharma (Euronext Paris:ABNX), a biopharma company focused on breakthrough biotherapies to address life-threatening conditions with no effective treatments, announced on Wednesday that it is in advanced strategic discussions with IHU SEPSIS, the world's leading centre dedicated to sepsis research, training, and clinical care.

The partnership aims to create the first fully integrated global platform for the treatment of sepsis by combining ABIONYX Pharma's proprietary technology with IHU SEPSIS's academic and hospital expertise.

IHU SEPSIS unites 60 research teams, representing 275 researchers and 94 clinical physicians, collaborating with global organisations including the Global Sepsis Alliance and Sepsis Canada. Its international reach enables the implementation of multi-country clinical studies across North America, Europe, and emerging markets, facilitating the worldwide validation of new therapeutic approaches.

The discussions follow scientific validation of the genetic causality of apoA-I in sepsis, published in Scientific Reports (Nature), reinforcing ABIONYX Pharma's therapeutic strategy targeting immune-inflammatory dysfunctions. This recognition has drawn growing interest from institutional investors, industry leaders, and patient organisations.

Both parties are progressing toward finalising a long-term, high-visibility alliance designed to accelerate clinical development, enhance scientific impact, and strengthen ABIONYX Pharma's institutional credibility. The agreement is expected to mark a pivotal step in the company's strategic and financial growth trajectory.